Egis And mAbxience Ally On Multiple Biosimilars In CEE
Agreement For Two Candidates Could Expand To Cover More Markets
Fresenius Kabi-controlled mAbxience has struck a deal with Servier’s Egis Pharmaceutical to commercialize two biosimilar candidates in multiple central and eastern European markets.
